SCHEMBL6715481

SCHEMBL6715481

COC(=O)c1ccccc1NC(=O)C(NC(=S)Nc1ccc(OC)cc1[N+](=O)[O-])c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 12/20 0.56
MAPT P10636 11/20 0.56
MEN1 O00255 11/20 0.56
KMT2A Q03164 11/20 0.56
NPSR1 Q6W5P4 5/20 0.56
TDP1 Q9NUW8 4/20 0.56
POLB P06746 2/20 0.56
OPRK1 P41145 1/20 0.56
HTT P42858 4/20 0.54
LMNA P02545 4/20 0.54
TP53 P04637 2/20 0.54
AKR1C3 P42330 1/20 0.53
AKR1C2 P52895 1/20 0.53
SMN1; SMN2 Q16637 5/20 0.53
RAB9A P51151 4/20 0.53
NPC1 O15118 3/20 0.53
MAPK1 P28482 1/20 0.53
KDM4E B2RXH2 1/20 0.52
NPY1R P25929 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6715736 0.91 ALDH1A1 (0.60) ALDH1A1MAPTMEN1KMT2ATDP1
SCHEMBL6715664 0.89 MEN1 (0.56) ALDH1A1MAPTMEN1KMT2ANPSR1
SCHEMBL8347861 0.89 MEN1 (0.56) ALDH1A1MAPTMEN1KMT2ANPSR1
SCHEMBL6715739 0.89 MEN1 (0.56) ALDH1A1MAPTMEN1KMT2ANPSR1
SCHEMBL6714416 0.88 ALDH1A1 (0.62) ALDH1A1MAPTMEN1KMT2ANPSR1
SCHEMBL6723442 0.88 MEN1 (0.58) ALDH1A1MAPTMEN1KMT2ANPSR1
SCHEMBL8345935 0.88 MEN1 (0.59) ALDH1A1MAPTMEN1KMT2ANPSR1
SCHEMBL6716931 0.87 MEN1 (0.54) ALDH1A1MAPTMEN1KMT2ANPSR1
SCHEMBL6716886 0.85 MAPT (0.58) ALDH1A1MAPTMEN1KMT2ANPSR1
SCHEMBL6719450 0.85 MAPT (0.57) ALDH1A1MAPTMEN1KMT2ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed
WO-2004022534-A1 ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors SLC1A2, SLC6A7, SLC1A1 ALDH1A1 572/4885MAPT 427/4885MEN1 2933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.